102 related articles for article (PubMed ID: 14727862)
1. Liposomal budesonide for dry powder inhaler: preparation and stabilization.
Joshi MR; Misra A
AAPS PharmSciTech; 2001 Nov; 2(4):25. PubMed ID: 14727862
[TBL] [Abstract][Full Text] [Related]
2. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization.
Joshi M; Misra A
Int J Pharm; 2001 Jul; 223(1-2):15-27. PubMed ID: 11451628
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.
Chennakesavulu S; Mishra A; Sudheer A; Sowmya C; Suryaprakash Reddy C; Bhargav E
Asian J Pharm Sci; 2018 Jan; 13(1):91-100. PubMed ID: 32104382
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary disposition of budesonide from liposomal dry powder inhaler.
Joshi M; Misra AN
Methods Find Exp Clin Pharmacol; 2001 Dec; 23(10):531-6. PubMed ID: 11957743
[TBL] [Abstract][Full Text] [Related]
5. Development of liposomal amphotericin B dry powder inhaler formulation.
Shah SP; Misra A
Drug Deliv; 2004; 11(4):247-53. PubMed ID: 15371106
[TBL] [Abstract][Full Text] [Related]
6. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
Stevens PJ; Lee RJ
Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
[TBL] [Abstract][Full Text] [Related]
7. Liposomal dry powders as aerosols for pulmonary delivery of proteins.
Lu D; Hickey AJ
AAPS PharmSciTech; 2005 Dec; 6(4):E641-8. PubMed ID: 16408866
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
AAPS PharmSciTech; 2004 Aug; 5(4):e65. PubMed ID: 15760062
[TBL] [Abstract][Full Text] [Related]
9. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma.
Reichel W; Dahl R; Ringdal N; Zetterstrom O; van den Elshout FJ; Laitinen LA
Int J Clin Pract; 2001 Mar; 55(2):100-6. PubMed ID: 11321849
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
Pharmazie; 2004 Oct; 59(10):812-3. PubMed ID: 15544064
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
Bhatia A; Kumar R; Katare OP
J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
[TBL] [Abstract][Full Text] [Related]
12. Effects of mild processing pressures on the performance of dry powder inhaler formulations for inhalation therapy. 1: Budesonide and lactose.
Marek SR; Donovan MJ; Smyth HD
Eur J Pharm Biopharm; 2011 May; 78(1):97-106. PubMed ID: 21182942
[TBL] [Abstract][Full Text] [Related]
13. Adrenal suppression in asthmatic children receiving low-dose inhaled budesonide: comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer.
Goldberg S; Einot T; Algur N; Schwartz S; Greenberg AC; Picard E; Virgilis D; Kerem E
Ann Allergy Asthma Immunol; 2002 Dec; 89(6):566-71. PubMed ID: 12487221
[TBL] [Abstract][Full Text] [Related]
14. The effects of lyophilization on the stability of liposomes containing 5-FU.
Glavas-Dodov M; Fredro-Kumbaradzi E; Goracinova K; Simonoska M; Calis S; Trajkovic-Jolevska S; Hincal AA
Int J Pharm; 2005 Mar; 291(1-2):79-86. PubMed ID: 15707734
[TBL] [Abstract][Full Text] [Related]
15. Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study.
Naikwade SR; Bajaj AN; Gurav P; Gatne MM; Singh Soni P
AAPS PharmSciTech; 2009; 10(3):993-1012. PubMed ID: 19649711
[TBL] [Abstract][Full Text] [Related]
16. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma.
Corren J; Berkowitz R; Murray JJ; Prenner B
Int J Clin Pract; 2003 Sep; 57(7):567-72. PubMed ID: 14529054
[TBL] [Abstract][Full Text] [Related]
17. Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristics.
Coowanitwong I; Arya V; Patel G; Kim WS; Craciun V; Rocca JR; Singh R; Hochhaus G
J Pharm Pharmacol; 2007 Nov; 59(11):1473-84. PubMed ID: 17976257
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of inhalational liposomal system of budesonide for better management of asthma.
Parmar JJ; Singh DJ; Hegde DD; Lohade AA; Soni PS; Samad A; Menon MD
Indian J Pharm Sci; 2010 Jul; 72(4):442-8. PubMed ID: 21218054
[TBL] [Abstract][Full Text] [Related]
19. Release stability of 5-fluorouracil liposomal concentrates, gels and lyophilized powder.
Nounou MM; El-Khordagui LK; Khalafallah N
Acta Pol Pharm; 2005; 62(5):381-91. PubMed ID: 16459487
[TBL] [Abstract][Full Text] [Related]
20. Effect of sucrose as a lyoprotectant on the integrity of paclitaxel-loaded liposomes during lyophilization.
Kannan V; Balabathula P; Thoma LA; Wood GC
J Liposome Res; 2015; 25(4):270-8. PubMed ID: 25534990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
